Cargando…
Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects
AIMS: Emodepside is an anthelmintic, originally developed for veterinary use. We investigated in healthy subjects the safety, and pharmacokinetics of a liquid service formulation (LSF) and immediate release (IR) tablet of emodepside in 2 randomised, parallel‐group, placebo‐controlled, Phase I studie...
Autores principales: | Gillon, Jean‐Yves, Dennison, Jeremy, van den Berg, Frans, Delhomme, Sophie, Dequatre Cheeseman, Karen, Peña Rossi, Claudia, Strub Wourgaft, Nathalie, Specht, Sabine, Pedrique, Belén, Monnot, Frédéric, Skrabs, Susanne, Rodriguez, Maria‐Luisa, Stass, Heino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518114/ https://www.ncbi.nlm.nih.gov/pubmed/33759250 http://dx.doi.org/10.1111/bcp.14816 |
Ejemplares similares
-
Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
por: Assmus, Frauke, et al.
Publicado: (2022) -
Development of emodepside as a possible adulticidal treatment for human onchocerciasis—The fruit of a successful industrial–academic collaboration
por: Krücken, Jürgen, et al.
Publicado: (2021) -
Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis
por: Bah, Germanus S., et al.
Publicado: (2021) -
Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside
por: Hübner, Marc P., et al.
Publicado: (2021) -
The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030
por: Vinkeles Melchers, Natalie V. S., et al.
Publicado: (2021)